Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Ray-Coquard

Showing results (261-270 of 509) with videos related to

Pageof 51
Sort By:
BMC Health Services Research|January 6, 2018
Being treated in higher volume hospitals leads to longer progression-free survival for epithelial ovarian carcinoma patients in the Rhone-Alpes region of FranceMarius Huguet, Lionel Perrier, Olivia Bally, et al.
The Oncologist|December 7, 2018
Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective StudyGiovanni Fucà, Nadia Hindi, Isabelle Ray-Coquard, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2015
Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma GroupAnna Patrikidou, Julien Domont, Sylvie Chabaud, et al.
Bulletin Du Cancer|March 30, 2012
Multidisciplinarity and medical decision, impact for patients with cancer: sociological assessment of two tumour committees' organizationPatrick Castel, Louis Tassy, Antoine Lurkin, et al.
European Journal of Cancer (Oxford, England : 1990)|December 19, 2012
CD4 lymphopenia to identify end-of-life metastatic cancer patientsJulien Péron, Claire Cropet, Olivier Tredan, et al.
Therapeutic Advances in Medical Oncology|August 11, 2025
Immune landscape and TAM density in endometrial cancer: implications for immune checkpoint inhibitors efficacyOlivia Le Saux, Renaud Sabatier, Isabelle Treilleux, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 1, 2021
Cutting Edge: mTORC1 Inhibition in Metastatic Breast Cancer Patients Negatively Affects Peripheral NK Cell Maturation and NumberLaurie Besson, Benoite Mery, Magali Morelle, et al.
Journal of Gynecologic Oncology|August 11, 2021
Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trialKeiichi Fujiwara, Hiroyuki Fujiwara, Hiroyuki Yoshida, et al.
Personalized Medicine|May 2, 2018
A comparison of Australian and French families affected by sarcoma: perceptions of genetics and incidental findingsVictoria Rasmussen, Laura E Forrest, Muriel Rogasik, et al.
Bulletin Du Cancer|January 30, 2026
[French recommendations for clinical practice, Nice-Saint-Paul-de-Vence 2024-2025: Management of localized cervical cancer]Cyrus Chargari, Alejandra Martinez, Judith Michels, et al.
Pageof 51

Showing results (261-270 of 509) with videos related to

Sort By:
Pageof 51
BMC Health Services Research|January 6, 2018
Being treated in higher volume hospitals leads to longer progression-free survival for epithelial ovarian carcinoma patients in the Rhone-Alpes region of FranceMarius Huguet, Lionel Perrier, Olivia Bally, et al.
The Oncologist|December 7, 2018
Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective StudyGiovanni Fucà, Nadia Hindi, Isabelle Ray-Coquard, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2015
Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma GroupAnna Patrikidou, Julien Domont, Sylvie Chabaud, et al.
Bulletin Du Cancer|March 30, 2012
Multidisciplinarity and medical decision, impact for patients with cancer: sociological assessment of two tumour committees' organizationPatrick Castel, Louis Tassy, Antoine Lurkin, et al.
European Journal of Cancer (Oxford, England : 1990)|December 19, 2012
CD4 lymphopenia to identify end-of-life metastatic cancer patientsJulien Péron, Claire Cropet, Olivier Tredan, et al.
Therapeutic Advances in Medical Oncology|August 11, 2025
Immune landscape and TAM density in endometrial cancer: implications for immune checkpoint inhibitors efficacyOlivia Le Saux, Renaud Sabatier, Isabelle Treilleux, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 1, 2021
Cutting Edge: mTORC1 Inhibition in Metastatic Breast Cancer Patients Negatively Affects Peripheral NK Cell Maturation and NumberLaurie Besson, Benoite Mery, Magali Morelle, et al.
Journal of Gynecologic Oncology|August 11, 2021
Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trialKeiichi Fujiwara, Hiroyuki Fujiwara, Hiroyuki Yoshida, et al.
Personalized Medicine|May 2, 2018
A comparison of Australian and French families affected by sarcoma: perceptions of genetics and incidental findingsVictoria Rasmussen, Laura E Forrest, Muriel Rogasik, et al.
Bulletin Du Cancer|January 30, 2026
[French recommendations for clinical practice, Nice-Saint-Paul-de-Vence 2024-2025: Management of localized cervical cancer]Cyrus Chargari, Alejandra Martinez, Judith Michels, et al.
Pageof 51